Astrazeneca Ab

Astra Aktiebolag

Eifion D Phillips

John E Macor

Hui-Fang Chang

Richard Schmiesing

Robert Mack

Simon Semus

George Byron Mullen

Yan Li

James T Loch, Iii

Glen E Ernst

James Empfield

Rebecca Urbanek

Michael Balestra

James Woods

Thomas Richard Simpson

Timothy Piser

Scott Throner

Richard Alan Keith

Dennis J McCarthy

Christopher Holmquist

Hui Xiong

Peter Dorff

John Gordon

John Richard Heys

Mark A Smith

A radioactive compound having the formula:  and pharmaceutically-acceptable salts thereof, wherein Rand Ar are as defined in the specification, enantiomers, in vivo-hydrolysable precursors, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them and uses of them for diagnostic and analytic purposes.

Ligands

Nicotinic acetylcholine receptor ligands of Formula I wherein X, n, Rand Rare as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing, and methods for using the same.

Nicotinic acetylcholine receptor ligands 101

Compounds of formula I: wherein Ar is a moiety of formula II or III: and pharmaceutically-acceptable salts thereof, wherein A, B, and Rare as defined in the specification, enantiomers, in vivo-hydrolysable precursors, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them and uses of them for diagnostic and analytic purposes.

Spirofuropyridine aryl derivatives

Compounds of formula I: and pharmaceutically-acceptable salts thereof, wherein Q, Ar, A and Arare as defined in the specification, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them, uses of them as medicaments for therapy, uses of them in the manufacture of medicaments and uses of them for diagnostic and analytic purposes.

Oxazolidinone nicotinic acetylcholine receptor agonists

A pharmaceutical composition comprising a compound of formula wherein n, m, p, X, Y, W, A, G and D are as defined in the specification, enantiomers thereof, or pharmaceutically acceptable salts thereof, its use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.

Spiroazabicyclic heterocyclic compounds

Compounds of formula I: wherein A, D, Ar, E and Arare as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.

2-(pyridine-4-yl)-N-(quinuclidin-2-yl)thiazole-4-carboxide nicotinic acetylcholine receptor ligands

Compounds of Formula I: and pharmaceutically-acceptable salts thereof, wherein Q, E and D are as defined in the specification, enantiomers, in vivo-hydrolysable precursors, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them and uses of them for diagnostic and analytic purposes.

Non-amide nonanes

Compounds of formula I: and pharmaceutically-acceptable salts thereof, wherein Ar and R are as defined in the specification, compositions containing such compounds and methods of using such compounds and compositions in therapy.

Furyl compounds

Compounds of formula I: and pharmaceutically-acceptable salts thereof, wherein Ar and R are as defined in the specification, compositions containing such compounds and the use of such compounds and compositions for use in therapy.

Heterocyclic compounds

Compounds of formula I: wherein A and Rare as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.

4-substituted imidazoles

Compounds

Methods for the treatment of psychotic or intellectual impairment disorders with compounds of formula I, wherein A, R and Rare as defined in the specification.

Substituted amines of spirofuropyridines useful in therapy

A compound having the formula I: and pharmaceutically-acceptable salts thereof, wherein Ar and R are as defined in the specification, compositions containing such compounds and the use of such compounds and compositions for use in therapy.

Thienyl compounds

Compounds of formula I:wherein A, D, Ar, E and Arare as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.

A compound of formula I,wherein NRRis attached at the 5- or 6-position of the furopyridine ring; R is hydrogen, C&#x2013;Calkyl, or COR; Ris (CH)Ar, CHCH&#x2550;CHAr, or CHC&#x2261;CAr; n is 0 to 3; A is N or NO; Ar is a 5- or 6-membered aromatic or heteroaromatic ring which contains zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; or an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur, any of which may optionally be substituted with one to two substitutents independently selected from: halogen, trifluoromethyl, or C&#x2013;Calkyl; Ris hydrogen, C&#x2013;Calkyl, C&#x2013;Calkoxy or phenyl ring optionally substituted with one to three of the following substituents: halogen, C&#x2013;Calkyl, C&#x2013;Calkenyl, C&#x2013;Calkynyl, OH; OC&#x2013;Calkyl, COR, &#x2014;CN, &#x2014;NO, &#x2014;NRR, or &#x2014;CF; R, Rand Rmay be hydrogen, C&#x2013;Calkyl, or phenyl ring optionally substituted with one to three of the following substituents: halogen, C&#x2013;Calkyl, C&#x2013;Calkenyl, C&#x2013;Calkynyl, OH; OC&#x2013;Calkyl, &#x2014;CN, &#x2014;NO, or &#x2014;CF; and enantiomers thereof, and pharmaceutically acceptable salts thereof, processes for preparing them, composition containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.

Growing community of inventors

Worcester, MA, United States of America

Eifion D Phillips